AOD-9604 : Additional support with body composition, particularly when a non-GLP-1 approach is preferred as part of a broader metabolic strategy
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
B12 Injections What are Vitamin B12 Injections
Diabetes 69 , 11781192 (2020)
Emily Kirby oversees our weight loss medications so that you receive an FDA-approved product, the appropriate dosage, and personalized, ongoing care and support
Are there side effects unique to either form
